Risk Variants Associated With Normal Pressure Hydrocephalus Genome-Wide Association Study in the FinnGen Cohort
: Räsänen, Joel; Heikkinen, Sami; Mäklin, Kiira; Lipponen, Anssi; Kuulasmaa, Teemu; Mehtonen, Juha; Korhonen, Ville E.; Junkkari, Antti; Grenier-Boley, Benjamin; Bellenguez, Celine; Oinas, Minna; Avellan, Cecilia; Frantzén, Janek; Kotkansalo, Anna; Rinne, Jaakko; Ronkainen, Antti; Kauppinen, Mikko; zu Fraunberg, Mikael von Und; Lönnrot, Kimmo; Satopää, Jarno; Perola, Markus; Koivisto, Anne M.; Julkunen, Valtteri; Portaankorva, Anne M.; Mannermaa, Arto; Soininen, Hilkka; Helisalmi, Seppo; Jääskeläinen, Juha E.; Lambert, Jean-Charles; Eide, Per K.; Palotie, Aarno; Kurki, Mitja I.; Hiltunen, Mikko; Leinonen, Ville
Publisher: LIPPINCOTT WILLIAMS & WILKINS
: PHILADELPHIA
: 2024
: Neurology
: NEUROLOGY
: e209694
: 103
: 5
: 13
: 0028-3878
: 1526-632X
DOI: https://doi.org/10.1212/WNL.0000000000209694
: https://doi.org/10.1212/WNL.0000000000209694
: https://research.utu.fi/converis/portal/detail/Publication/457696714
Background and Objectives
Large-scale genome-wide studies of chronic hydrocephalus have been lacking. We conducted a genome-wide association study (GWAS) in normal pressure hydrocephalus (NPH).
Methods
We used a case-control study design implementing FinnGen data containing 473,691 Finns with genotypes and nationwide health records. Patients with NPH were selected based on ICD-10 G91.2 diagnosis. To select patients with idiopathic NPH (iNPH) for sensitivity analysis, we excluded patients with a potentially known etiology of the condition using an algorithm on their disease history. The controls were the remaining non-hydrocephalic participants. For a replication analysis, the NPH cohort from UK Biobank (UKBB) was used.
Results
We included 1,522 patients with NPH (mean age 72.2 years, 53% women) and 451,091 controls (mean age 60.5 years, 44% women). In the GWAS comparing patients with NPH with the controls, we identified 6 gene regions significantly (p < 5.0e-8) associated with NPH that replicated in a meta-analysis with UKBB (NPH n = 173). The top loci near the following genes were rs7962263, SLCO1A2 (odds ratio [OR] 0.71, 95% CI 0.65-0.78, p = 1.0e-14); rs798495, AMZ1/GNA12 (OR 1.29, 95% CI 1.20-1.39, p = 2.9e-12); rs10828247, MLLT10 (OR 0.77, 95% CI 0.71-0.83, p = 1.5e-11); rs561699566 and rs371919113, CDCA2 (OR 0.76, 95% CI 0.70-0.82, p = 1.5e-11); rs56023709, C16orf95 (OR 1.24, 95% CI 1.16-1.33, p = 3.0e-9); and rs62434144, PLEKHG1 (OR 1.23, 95% CI 1.14-1.32, p = 1.4e-8). In the sensitivity analysis comparing only patients with iNPH (n = 1,055) with the controls (n = 451,091), 4 top loci near the following genes remained significant: rs7962263, SLCO1A2 (OR 0.70, 95% CI 0.63-0.78, p = 2.1e-11); rs10828247, MLLT10 (OR 0.74, 95% CI 0.62-0.82, p = 4.6e-10); rs798511, AMZ1/GNA12 (OR 1.28, 95% CI 1.17-1.39, p = 1.7e-8); and rs56023709, C16orf95 (OR 1.28, 95% CI 1.17-1.39, p = 1.7e-8).
Discussion
We identified 6 loci significantly associated with NPH in the thus far largest GWAS in chronic hydrocephalus. The genes near the top loci have previously been associated with blood-brain barrier and blood-CSF barrier function and with increased lateral brain ventricle volume. The effect sizes and allele frequencies remained similar in NPH and iNPH cohorts, indicating the identified loci are risk determinants for iNPH and likely not explained by associations with other etiologies. However, the exact role of these loci is still unknown, warranting further studies.
:
The FinnGen project is funded by 2 grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd., Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKlineIntellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc., NovartisAG, and Boehringer Ingelheim International GmbH. This study was funded by the Academy of Finland (grant number 338182), KUH VTR Fund, Sigrid Juselius Foundation, Finnish Medical Foundation, JPND-JPcofuND; EADB (grant 301220), Finnish Cultural Foundation, Maire Taponen Foundation, and the Strategic Neuroscience Funding of the University of Eastern Finland.